Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Algovita Spinal Cord Stimulation System Hi-Fi Study

9 mars 2021 uppdaterad av: Nuvectra

Clinical Trial Comparing Ultra-High Versus Traditional Pulse Widths Using the ALGOVITA® SCS System High Fidelity Stimulation in the Treatment of Persistent or Recurrent Back and/or Leg Pain Following Spinal Surgery

The objective of this study is to obtain post-market clinical outcome data for the Algovita SCS System when used on-label, according to the applicable directions for use, using high fidelity tonic stimulation at either ultra-high pulse width or traditional pulse width for the treatment of persistent or recurrent back and/or leg pain following spinal surgery.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

20

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Förenta staterna
    • Arizona
      • Tucson, Arizona, Förenta staterna, 85712
        • Pain Institute of Southern Arizona
    • California
      • Newport Beach, California, Förenta staterna, 92660
        • Newport Beach Headache & Pain
      • Santa Rosa, California, Förenta staterna, 95401
        • Summit Pain Alliance
    • Colorado
      • Colorado Springs, Colorado, Förenta staterna, 80919
        • Spinal Diagnostics & Pain Management
    • Kansas
      • Overland Park, Kansas, Förenta staterna, 66210
        • Mid-America PolyClinic & Interventional Pain Management Specialists
    • Louisiana
      • Shreveport, Louisiana, Förenta staterna, 71105
        • WK River Cities Clinical Research Center
    • Massachusetts
      • Chestnut Hill, Massachusetts, Förenta staterna, 02467
        • Brigham & Women's Hospital
    • Ohio
      • Chillicothe, Ohio, Förenta staterna, 45601
        • Adena Spine Center
      • Cleveland, Ohio, Förenta staterna, 44195
        • Cleveland Clinic Foundation
    • Rhode Island
      • Providence, Rhode Island, Förenta staterna, 02903
        • Comprehensive Spine Center at Rhode Island Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patients with FBSS defined as persistent or recurrent back and/or leg pain despite one or more anatomically successful back surgeries for the same original pain.
  • Age 18-75 years old at consent.
  • Targeted pain intensity of ≥ 5 out of 10 on the Baseline visit NRS.
  • ODI score of 41-80 out of 100 at the Baseline visit.
  • Appropriate candidate for the surgical procedure and Algovita SCS therapy based on the clinical judgment of the investigator and the Algovita Instructions for Provider (IFP) in the Nuvectra product manuals.
  • On stable pain medications for at least 28 days prior to consent. Stable is defined as no new or discontinued pain medications and no changes to total daily dose of any pain medications.
  • Willing and capable of providing informed consent.
  • Willing and able of complying with the study-related requirements, procedures, and visits.
  • Speaks English as a primary language (as the Algovita patient manuals are only currently available in English).
  • Has adequate cognitive ability to use the subject devices (e.g., PPC, PoP), as determined by the investigator.

Exclusion Criteria:

  • Has a medical/psychological/psychiatric condition/disorder that could interfere with study procedures as determined by the investigator.
  • Has a coexisting pain condition that might confound pain ratings, as determined by the investigator.
  • Has a condition currently requiring or likely to require the use of MRI or diathermy.
  • Has an existing drug pump, SCS System, or other active implantable device.
  • Has any prior SCS experience.
  • Pregnant or planning to become (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile, or be at least 2 years postmenopausal).
  • For subjects with diabetes, HbA1c ≥ 8.5% as measured at the Baseline visit (or within the 3 months prior to the Baseline visit).
  • Participating in another clinical trial that could affect the outcomes or requirements of this study as determined by the investigator.
  • Involved in an injury claim under current litigation or have a pending or approved workers compensation claim.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Trippel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Ultra-high pulse width
Ultra-high pulse width stimulation using the Algovita System
Enhet: Ultra-high pulse width stimulation
Algovita Spinal Cord Stimulation System with associated components
Aktiv komparator: Traditional pulse width
Traditional pulse width stimulation using the Algovita System
Enhet: Traditional pulse width stimulation
Algovita Spinal Cord Stimulation System with associated components

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Effectiveness of targeted pain reduction compared to baseline in each treatment arm
Tidsram: Week 25

The percentage of participants who experience at least a 50 percent reduction in targeted pain from baseline, as assessed by Numeric Rating Scale (NRS). The Numeric Rating Scale (NRS) will range from 0 to 10 with a higher score indicating a higher level of pain.

Effectiveness will be compared both descriptively and statistically between the two randomized treatment groups using crossover analysis methods.
Week 25
Rate of serious study-related adverse events (AEs) in each treatment arm
Tidsram: From Permanent Implant through Week 25
The rate of serious study-related AEs. Study-related AEs are defined as any device, procedure and therapy/stimulation-related AEs.
From Permanent Implant through Week 25

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Effectiveness of targeted pain reduction compared to baseline in each treatment arm
Tidsram: Week 12 and Months 12, 18 and 24
The percentage of participants who experience at least a 50 percent reduction in targeted pain as assessed by Numeric Rating Scale (NRS). The Numeric Rating Scale (NRS) will range from 0 to 10 with a higher score indicating a higher level of pain.
Week 12 and Months 12, 18 and 24
Effectiveness of back and/or leg pain reduction compared to baseline in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
The percentage of participants who experience at least a 50 percent reduction in back and/or leg pain as assessed by Numeric Rating Scale (NRS). The Numeric Rating Scale (NRS) will range from 0 to 10 with a higher score indicating a higher level of pain.
Weeks 12 and 25, and Months 12, 18 and 24
Effectiveness of targeted, back and/or leg pain reduction compared to baseline in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
The percentage of participants who experience at least a 50 percent reduction in targeted, back and/or leg pain as assessed by a Visual Analog Scale (VAS). The Visual Analog Scale (VAS) will range from 0 mm (no pain) to 100 mm (worst pain imaginable). A higher score indicates a higher level of pain.
Weeks 12 and 25, and Months 12, 18 and 24
Change in targeted, back and/or leg pain compared to baseline in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
The mean change and percent change from baseline in targeted, back and/or leg pain as assessed by a Numeric Rating Scale (NRS). The Numeric Rating Scale (NRS) will range from 0 to 10 with a higher score indicating a higher level of pain.
Weeks 12 and 25, and Months 12, 18 and 24
Change in targeted, back and/or leg pain compared to baseline in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
The mean change and percent change from baseline in targeted, back and/or leg pain as assessed by a Visual Analog Scale (VAS). The Visual Analog Scale (VAS) will range from 0 mm (no pain) to 100 mm (worst pain imaginable). A higher score indicates a higher level of pain.
Weeks 12 and 25, and Months 12, 18 and 24
Clinician Global Impression of Change score in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
The Investigator's assessment of change in the overall status of the participant using the standard Clinician Global Impression of Change ranging from 1 (very much improved) to 7 (very much worse).
Weeks 12 and 25, and Months 12, 18 and 24
Change in disability compared to baseline in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
The change from baseline in disability as measured by the Oswestry Disability Index. The Oswestry Disability Index is scored between 0 and 100 with higher scores indicating a greater disability.
Weeks 12 and 25, and Months 12, 18 and 24
Change in quality of life compared to baseline in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
The change from baseline in quality of life as measured by the EQ-5D-5L, a standardized measure of health status.
Weeks 12 and 25, and Months 12, 18 and 24
Change in patient activity per the Pain Disability Index score in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
The change from baseline in patient activity as measured by the Pain Disability Index score. The Pain Disability Index is a self-report asking participants to rate how much pain interferes in seven areas of life activity using a 0 (no disability) to 10 (total disability) numeric rating scale.
Weeks 12 and 25, and Months 12, 18 and 24
Patient Global Impression of Change score in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
The participant's assessment of change in their overall status using the standard Patient Global Impression of Change ranging from 1 (very much improved) to 7 (very much worse).
Weeks 12 and 25, and Months 12, 18 and 24
Participant satisfaction per the subject satisfaction survey outcome in each treatment arm
Tidsram: Weeks 12 and 25, and Months 12, 18 and 24
Participant satisfaction using a subject satisfaction survey (5 point Likert scale format) ranging from very satisfied to very dissatisfied.
Weeks 12 and 25, and Months 12, 18 and 24
Evaluation of trial success rates
Tidsram: From Trial Implant to End of Trail
The percentage of participants that have a successful trial phase, defined as at least a 50 percent reduction in targeted pain compared to baseline.
From Trial Implant to End of Trail
Rate of surgical re-intervention of the SCS system
Tidsram: From Permanent Implant through Month 24
Rate of surgical re-intervention of the SCS system for participants with a permanent implant.
From Permanent Implant through Month 24

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Nuvectra

Samarbetspartners

Bright Research Partners

Utredare

  • Studierektor: Ben Tranchina, Nuvectra

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

2 november 2018

Primärt slutförande (Faktisk)

27 april 2020

Avslutad studie (Faktisk)

27 april 2020

Studieregistreringsdatum

Först inskickad

26 juli 2018

Först inskickad som uppfyllde QC-kriterierna

7 augusti 2018

Första postat (Faktisk)

9 augusti 2018

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

11 mars 2021

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 mars 2021

Senast verifierad

1 mars 2021

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • CLRE 1092

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Kronisk smärta

Kliniska prövningar på Ultra-high pulse width stimulation

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Peru

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

Prenumerera